Metabolism Disorder TRIZ Cases

Irisin protects beta-cells from lipotoxic damage while improving peripheral insulin sensitivity.

GLP1R-specific CAR-Tregs resolve systemic immunosuppression by concentrating immune suppression at autoimmune sites.

IL1RA-derived peptides bind IL-1 receptors to block inflammatory signaling, reducing kidney injury biomarkers and halting diabetic nephropathy progression.

Boronic acid crosslinked liposomes release encapsulated insulin upon glucose detection, eliminating manual monitoring and injection requirements.

Antisense molecules inhibit DMK and MRCKβ expression to reduce AI4-like T cell activity, preventing pancreatic beta cell destruction.

Amino acid substitutions in calcitonin analogs reduce bone anti-resorptive side effects while maintaining appetite suppression.

A Cirsium-derived inhibitor suppresses fatty acid synthase to resolve ineffective fat accumulation in current treatments.

Enzyme-rich malt extract with carbohydrases reduces fermentation activity to alleviate enterometabolic disorder symptoms.

A protein-based dietary composition featuring a specific lysine to tryptophan weight ratio between 2.5 and 4.

Modified PYY peptides overcome resistance in severely obese patients by enhancing metabolic stability and receptor binding affinity.

Conjugating oligosaccharides to GLP-1 peptides extends half-life and reduces antigenicity without adverse reactions.

Incorporating okra gum and cactus mucilage raises the Trouton ratio above six, reducing aspiration risk for dysphagia patients.

Hafnia alvei expresses ClpB protein that mimics alpha-MSH to activate MC4R receptors and stimulate satiety hormone release.

A multilayer coating system prevents adhesion and shape deformation of gelatin capsules during aqueous processing, ensuring stable combination therapy delivery.

Segmenting fermented mineral mixtures into bite-sized pills resolves the trade-off between high probiotic dosage and portability for constipation relief.

RUR20kD-IL-2 expands regulatory T cells via PEGylation to reduce autoimmune activity without severe adverse events.

Albumin facilitates C-peptide uptake by red blood cells, replacing invasive MRI scans with a rapid, low-cost biomarker assay.

Hydrophobic amino acid substitutions extend insulin plasma half-life, reducing hypoglycemia risk.

Human-derived monoclonal antibodies bind and neutralize multiple IFN-alpha subtypes with high affinity.

Nurr1 agonists activate skeletal muscle receptors to enhance glucose uptake, normalizing metabolic parameters without physical activity.

Deuterium enrichment in oxazolidinones retards metabolic reaction rates, enhancing stability while managing synthesis complexity.

A novel triterpenoid compound extracted from Momordica charantia L. inhibits hepatic gluconeogenesis and adipocyte differentiation to regulate metabolic disorders.

Human umbilical cord mesenchymal stem cell-derived small extracellular vesicles improve pancreatic islet function and increase beta cell mass.

A pharmaceutical composition combining zinc salt, cyclo-hispro, and antidiabetic drugs to regulate glucose levels.

Structured dose escalation of dulaglutide achieves enhanced glycemic control while minimizing gastrointestinal adverse events.

Functionalized calcium carbonate increases dissolved ion concentration through surface carboxylic acid modification.

Segmenting patients by HLA genotype enables tailored GAD or insulin-alum therapies that improve treatment efficacy despite increased protocol complexity.

A 2-monoacylglycerol degrading enzyme breaks down triglycerides in the digestive tract to delay fat absorption.

A swallowable capsule uses a pH-responsive actuator to expand and penetrate the intestinal wall for targeted drug release.

GLUT1 inhibitors reverse cardiac dysfunction in diabetic cardiomyopathy by reducing glucose uptake and preventing KLF5 upregulation.

Exendin-4 conjugated to haptocorrin binding substrates extends circulation time through specific protein-ligand interactions.

Facial skin bacterial diversity analysis identifies metabolic syndrome predisposition, enabling early intervention to delay onset of obesity and diabetes.

A prostaglandin transporter inhibitor with fluorine substituents modulates signaling pathways to treat metabolic and cardiovascular conditions.

Outward-projecting curved side edges prevent film-coating sticking while maintaining large volume without increasing thickness.

Covalent attachment of water-soluble polymers to ziconotide reduces renal clearance and extends in vivo half-life.

Controlled surface curvature and porosity in hydrogel capsules reduce fibrotic overgrowth while maintaining nutrient diffusion.

Ultrasonic cavitation extracts active compounds from sesame oil meal, inhibiting inflammatory cytokines and colon length reduction.

Modified GDF15 peptides resolve adverse effects from current treatments by reducing body weight and lowering plasma glucose levels.

Anti-CD3 antibody therapy administered before diagnosis preserves beta cell function and stabilizes metabolic responses in high-risk individuals.

Pulverized defatted sesame seeds inhibit fat absorption through physical adsorption.

Fluid-bed spray granulation converts low-dose linagliptin powder into uniform granules, resolving content segregation and chemical reactivity issues.

Anionic polymer conjugates encapsulate hydrophobic drugs within biodegradable micelles to enhance aqueous solubility.

Porous sorbent granules maintain high porosity and hardness while absorbing liquid formulations for rapid drug release.

Engineered polypeptides degrade immunogenic gluten peptides via site-directed mutagenesis, overcoming failure in harsh gastric acidity.

Segmented PET mesh scaffolds support alginate microcapsules to enable complete graft retrieval while maintaining cell containment.

Micronized solid pharmaceutical composition resolves capsule leakage and precipitation risks while maintaining dissolution performance.